This protocol defines the recommended approach for patients presenting with mildly to moderately active extensive ulcerative colitis — a specific disease state that calls for a structured induction strategy with defined endpoints for reassessment.
The patient has mildly to moderately active extensive ulcerative colitis. Disease extent and activity level together determine the appropriate treatment pathway, with induction of remission as the primary clinical objective.
Oral 5-ASA therapy is the recommended agent for induction in this setting. The full protocol specifies the minimum dose threshold required for efficacy, along with escalation criteria and the structured reassessment timeline — details available via the protocol below.
DOI: 10.14309/ajg.0000000000003463
In patients with mildly to moderately active extensive colitis, oral 5-ASA at a dose of at least 2.0 g daily is recommended to induce remission.
Patients with mildly to moderately active UC should be reassessed to determine response to induction therapy within 8 weeks.
In clinical trials, the definition of clinical remission has been a MES of 0 or 1, stool frequency of ≤1, and absence of rectal bleeding.
View source ↗